메뉴 건너뛰기




Volumn 99, Issue 3, 2014, Pages 219-226

Molecular genetics of peripheral T-cell lymphomas

Author keywords

Gene expression profiling; High throughput sequencing; Peripheral T cell lymphomas; Tyrosine kinases

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTINEOPLASTIC AGENT; BREAKPOINT CLUSTER REGION PROTEIN; CD20 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTOME;

EID: 84897373303     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1522-1     Document Type: Article
Times cited : (27)

References (73)
  • 2
    • 84867176445 scopus 로고    scopus 로고
    • New molecular insight into peripheral T cell lymphomas
    • Pileri SA, Piccaluga PP. New molecular insight into peripheral T cell lymphomas. J Clin Invest. 2012;122:3448-55.
    • (2012) J Clin Invest , vol.122 , pp. 3448-3455
    • Pileri, S.A.1    Piccaluga, P.P.2
  • 3
    • 56049100260 scopus 로고    scopus 로고
    • Peripheral T cell lymphoma, not otherwise specified: The stuff of genes, dreams and therapies
    • Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol. 2008;61:1160-7.
    • (2008) J Clin Pathol , vol.61 , pp. 1160-1167
    • Agostinelli, C.1    Piccaluga, P.P.2    Went, P.3    Rossi, M.4    Gazzola, A.5    Righi, S.6
  • 4
    • 51649091675 scopus 로고    scopus 로고
    • International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/ T-cell lymphoma study: Pathology findings and clinical outcomes
    • Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/ T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-30.
    • (2008) J Clin Oncol , vol.26 , pp. 4124-4130
    • Vose, J.1    Armitage, J.2    Weisenburger, D.3
  • 5
    • 47049084821 scopus 로고    scopus 로고
    • International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK? ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-cell Lymphoma Project
    • Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, et al. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK? ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood. 2008;111:5496-504.
    • (2008) Blood , vol.111 , pp. 5496-5504
    • Savage, K.J.1    Harris, N.L.2    Vose, J.M.3    Ullrich, F.4    Jaffe, E.S.5    Connors, J.M.6    Rimsza, L.7    Pileri, S.A.8
  • 6
    • 84887253698 scopus 로고    scopus 로고
    • Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: Results of a phase III diagnostic accuracy study
    • Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31:3019-25.
    • (2013) J Clin Oncol , vol.31 , pp. 3019-3025
    • Piccaluga, P.P.1    Fuligni, F.2    De Leo, A.3    Bertuzzi, C.4    Rossi, M.5    Bacci, F.6
  • 8
    • 77951906200 scopus 로고    scopus 로고
    • Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms
    • Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol. 2010;28:1583-90.
    • (2010) J Clin Oncol , vol.28 , pp. 1583-1590
    • Piva, R.1    Agnelli, L.2    Pellegrino, E.3    Todoerti, K.4    Grosso, V.5    Tamagno, I.6
  • 9
    • 77649206608 scopus 로고    scopus 로고
    • Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. International Peripheral T-Cell Lymphoma Project
    • Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. International Peripheral T-Cell Lymphoma Project. Blood. 2010;115:1026-36.
    • (2010) Blood , vol.115 , pp. 1026-1036
    • Iqbal, J.1    Weisenburger, D.D.2    Greiner, T.C.3    Vose, J.M.4    McKeithan, T.5    Kucuk, C.6
  • 11
    • 84880223497 scopus 로고    scopus 로고
    • Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: Alternative drivers in anaplastic large cell lymphoma
    • European T-cell Lymphoma Study Group
    • Tabbò F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G, European T-cell Lymphoma Study Group. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol. 2013;20:374-81.
    • (2013) Curr Opin Hematol , vol.20 , pp. 374-381
    • Tabbò, F.1    Ponzoni, M.2    Rabadan, R.3    Bertoni, F.4    Inghirami, G.5
  • 12
    • 84865197558 scopus 로고    scopus 로고
    • Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
    • Lemonnier F, Couronné L, Parrens M, Jaïs JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120:1466-9.
    • (2012) Blood , vol.120 , pp. 1466-1469
    • Lemonnier, F.1    Couronné, L.2    Parrens, M.3    Jaïs, J.P.4    Travert, M.5    Lamant, L.6
  • 13
  • 14
    • 84898660489 scopus 로고    scopus 로고
    • A targeted mutational landscape of angioimmunoblastic T cell lymphoma
    • Epub ahead of print
    • Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N. A targeted mutational landscape of angioimmunoblastic T cell lymphoma. Blood. 2013 (Epub ahead of print).
    • (2013) Blood
    • Odejide, O.1    Weigert, O.2    Lane, A.A.3    Toscano, D.4    Lunning, M.A.5    Kopp, N.6
  • 15
    • 85018246739 scopus 로고    scopus 로고
    • 55th ASH annual meeting and exposition
    • Schatz JH, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:843.
    • (2013) Blood , vol.122 , pp. 843
    • Schatz, J.H.1
  • 16
    • 84867256150 scopus 로고    scopus 로고
    • Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA
    • Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97:1594-602.
    • (2012) Haematologica , vol.97 , pp. 1594-1602
    • Delfau-Larue, M.H.1    De Leval, L.2    Joly, B.3    Plonquet, A.4    Challine, D.5    Parrens, M.6    Delmer, A.7
  • 18
    • 79960146011 scopus 로고    scopus 로고
    • Anaplastic large-cell lymphoma
    • European T-Cell Lymphoma Study Group. Review
    • Inghirami G, Pileri SA, European T-Cell Lymphoma Study Group. Anaplastic large-cell lymphoma. Semin Diagn Pathol. 2011;28:190-201 (Review).
    • (2011) Semin Diagn Pathol , vol.28 , pp. 190-201
    • Inghirami, G.1    Pileri, S.A.2
  • 22
  • 23
    • 85047699293 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
    • DOI 10.1038/sj/onc/1205152
    • Zamo' A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002; 21:1038-47. (Pubitemid 34174516)
    • (2002) Oncogene , vol.21 , Issue.7 , pp. 1038-1047
    • Zamo, A.1    Chiarle, R.2    Piva, R.3    Howes, J.4    Fan, Y.5    Chilosi, M.6    Levy, D.E.7    Inghirami, G.8
  • 26
    • 84876966952 scopus 로고    scopus 로고
    • Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study
    • Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472-80.
    • (2013) Lancet Oncol , vol.14 , pp. 472-480
    • Mossé, Y.P.1    Lim, M.S.2    Voss, S.D.3    Wilner, K.4    Ruffner, K.5    Laliberte, J.6
  • 31
    • 23944469381 scopus 로고    scopus 로고
    • The fully human anti-CD30 antibody 5F11 activates NF-kappaB and sensitizes lymphoma cells to bortezomib-induced apoptosis
    • DOI 10.1182/blood-2005-01-0427
    • Boll B, Hansen H, Heuck F, et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood. 2005;106:1839-42. (Pubitemid 41208602)
    • (2005) Blood , vol.106 , Issue.5 , pp. 1839-1842
    • Boll, B.1    Hansen, H.2    Heuck, F.3    Reiners, K.4    Borchmann, P.5    Rothe, A.6    Engert, A.7    Von Strandmann, E.P.8
  • 32
    • 0028837618 scopus 로고
    • In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts
    • Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 1995;55: 5335-41.
    • (1995) Cancer Res , vol.55 , pp. 5335-5341
    • Tian, Z.G.1    Longo, D.L.2    Funakoshi, S.3
  • 33
    • 67649908324 scopus 로고    scopus 로고
    • A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
    • Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171-9.
    • (2009) Br J Haematol , vol.146 , pp. 171-179
    • Forero-Torres, A.1    Leonard, J.P.2    Younes, A.3    Rosenblatt, J.D.4    Brice, P.5    Bartlett, N.L.6
  • 36
    • 78751692894 scopus 로고    scopus 로고
    • Discovery of recurrent t(6;7) (p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing
    • Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7) (p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117:915-9.
    • (2011) Blood , vol.117 , pp. 915-919
    • Feldman, A.L.1    Dogan, A.2    Smith, D.I.3    Law, M.E.4    Ansell, S.M.5    Johnson, S.H.6
  • 37
    • 84869221316 scopus 로고    scopus 로고
    • PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas
    • Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012;18:1699-704.
    • (2012) Nat Med , vol.18 , pp. 1699-1704
    • Laimer, D.1    Dolznig, H.2    Kollmann, K.3    Vesely, P.W.4    Schlederer, M.5    Merkel, O.6
  • 38
    • 0016237489 scopus 로고
    • Angio-immunoblastic lymphadenopathy with dysproteinemia
    • Frizzera G, Moran E, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinemia. Lancet. 1974;1:1070-3.
    • (1974) Lancet , vol.1 , pp. 1070-1073
    • Frizzera, G.1    Moran, E.2    Rappaport, H.3
  • 40
    • 0027300193 scopus 로고
    • B-cell lymphoma after angioimmunoblastic lymphadenopathy: A case with oligoclonal gene rearrangements associated with Epstein-Barr virus
    • Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood. 1993;82:241-6. (Pubitemid 23188770)
    • (1993) Blood , vol.82 , Issue.1 , pp. 241-246
    • Abruzzo, L.V.1    Schmidt, K.2    Weiss, L.M.3    Jaffe, E.S.4    Medeiros, L.J.5    Sander, C.A.6    Raffeld, M.7
  • 41
    • 0032052104 scopus 로고    scopus 로고
    • Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia
    • PII S092557109800005X
    • Matsue K, Itoh M, Tsukuda K, Kokubo T, Hirose Y. Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. Int J Hematol. 1998;67: 319-29. (Pubitemid 28257145)
    • (1998) International Journal of Hematology , vol.67 , Issue.3 , pp. 319-329
    • Matsue, K.1    Itoh, M.2    Tsukuda, K.3    Kokubo, T.4    Hirose, Y.5
  • 42
    • 0036798752 scopus 로고    scopus 로고
    • Angio-immunoblastic T cell lympboma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subytpe of AILD-TL?
    • DOI 10.1038/sj.leu.2402642
    • Lome-Maldonado C, Canioni D, Hermine O, et al. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection: a different subtype of AILD-TL? Leukemia. 2002;16:2134-41. (Pubitemid 35203459)
    • (2002) Leukemia , vol.16 , Issue.10 , pp. 2134-2141
    • Lome-Maldonado, C.1    Canioni, D.2    Hermine, O.3    Delabesse, E.4    Damotte, D.5    Raffoux, E.6    Gaulard, P.7    Macintyre, E.8    Brousse, N.9
  • 43
    • 33746877544 scopus 로고    scopus 로고
    • Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma
    • DOI 10.1097/01.pas.0000209855.28282.ce, PII 0000047820060700000003
    • Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802-10. (Pubitemid 44264969)
    • (2006) American Journal of Surgical Pathology , vol.30 , Issue.7 , pp. 802-810
    • Dorfman, D.M.1    Brown, J.A.2    Shahsafaei, A.3    Freeman, G.J.4
  • 45
    • 33746651491 scopus 로고    scopus 로고
    • Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells [6]
    • DOI 10.1182/blood-2006-01-0394
    • Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood. 2006;108:1110-1. (Pubitemid 44154657)
    • (2006) Blood , vol.108 , Issue.3 , pp. 1110-1111
    • Krenacs, L.1    Schaerli, P.2    Kis, G.3    Bagdi, E.4
  • 48
    • 69349093225 scopus 로고    scopus 로고
    • Interleukin-17 and type 17 helper T cells
    • Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888-98.
    • (2009) N Engl J Med , vol.361 , pp. 888-898
    • Miossec, P.1    Korn, T.2    Kuchroo, V.K.3
  • 49
    • 77957286394 scopus 로고    scopus 로고
    • Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma
    • Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177: 792-802.
    • (2010) Am J Pathol , vol.177 , pp. 792-802
    • Tripodo, C.1    Gri, G.2    Piccaluga, P.P.3    Frossi, B.4    Guarnotta, C.5    Piconese, S.6    Franco, G.7
  • 51
    • 27644555656 scopus 로고    scopus 로고
    • Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab [4]
    • DOI 10.1038/sj.leu.2403936, PII 2403936
    • Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G, Haas R. Complete remission in a patient withrelapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia. 2005;19:1993-5. (Pubitemid 41554011)
    • (2005) Leukemia , vol.19 , Issue.11 , pp. 1993-1995
    • Bruns, I.1    Fox, F.2    Reinecke, P.3    Kobbe, G.4    Kronenwett, R.5    Jung, G.6    Haas, R.7
  • 52
    • 0036121580 scopus 로고    scopus 로고
    • Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports
    • DOI 10.1080/10428190210190
    • Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) mayrespond to thalidomide treatment: two case reports. Leuk Lymphoma. 2002;43:133-7. (Pubitemid 34223981)
    • (2002) Leukemia and Lymphoma , vol.43 , Issue.1 , pp. 133-137
    • Strupp, C.1    Aivado, M.2    Germing, U.3    Gattermann, N.4    Haas, R.5
  • 53
    • 18644372042 scopus 로고    scopus 로고
    • Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide [3]
    • DOI 10.1038/sj.leu.2403710
    • Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia. 2005;19:873-5. (Pubitemid 40663113)
    • (2005) Leukemia , vol.19 , Issue.5 , pp. 873-875
    • Dogan, A.1    Ngu, L.S.P.2    Ng, S.H.3    Cervi, P.L.4
  • 54
    • 70349636649 scopus 로고    scopus 로고
    • Activity of lenalidamide in a phase II trial for T-cell lymphoma: Report on the first 24 cases
    • abstr 8524
    • Dueck GS, Chua N, Prasad A, Stewart D, White D, van der Jagt R, et al. Activity of lenalidamide in a phase II trial for T-cell lymphoma: report on the first 24 cases. J Clin Oncol. 2009; 27:439s (suppl; abstr 8524).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Dueck, G.S.1    Chua, N.2    Prasad, A.3    Stewart, D.4    White, D.5    Van Der Jagt, R.6
  • 55
    • 84899427557 scopus 로고    scopus 로고
    • 55th ASH annual meeting and exposition
    • Sakata-Yanagimoto M, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:815.
    • (2013) Blood , vol.122 , pp. 815
    • Sakata-Yanagimoto, M.1
  • 56
    • 84899434696 scopus 로고    scopus 로고
    • 55th ASH annual meeting and exposition
    • Palomero T, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:846.
    • (2013) Blood , vol.122 , pp. 846
    • Palomero, T.1
  • 57
    • 74049098626 scopus 로고    scopus 로고
    • High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus
    • Hartmann S, Gesk S, Scholtysik R, Kreuz M, Bug S, Vater I, et al. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. Br J Haematol. 2010;148:402-12.
    • (2010) Br J Haematol , vol.148 , pp. 402-412
    • Hartmann, S.1    Gesk, S.2    Scholtysik, R.3    Kreuz, M.4    Bug, S.5    Vater, I.6
  • 59
    • 58949084192 scopus 로고    scopus 로고
    • Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/ lymphoma
    • Nakagawa M, Nakagawa-Oshiro A, Karnan S, Tagawa H, Utsunomiya A, Nakamura S. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia/ lymphoma. Clin Cancer Res. 2009;15:30-8.
    • (2009) Clin Cancer Res , vol.15 , pp. 30-38
    • Nakagawa, M.1    Nakagawa-Oshiro, A.2    Karnan, S.3    Tagawa, H.4    Utsunomiya, A.5    Nakamura, S.6
  • 60
    • 33749241701 scopus 로고    scopus 로고
    • Peripheral T-cell lymphoma gene expression profiles
    • DOI 10.1002/hon.781
    • Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol. 2006;24:113-9. (Pubitemid 44483903)
    • (2006) Hematological Oncology , vol.24 , Issue.3 , pp. 113-119
    • Martinez-Delgado, B.1
  • 64
    • 31444450512 scopus 로고    scopus 로고
    • Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma
    • DOI 10.1038/sj.leu.2404045, PII 2404045
    • Streubel B, Vinatzer U, Willheim M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20:313-8. (Pubitemid 43148670)
    • (2006) Leukemia , vol.20 , Issue.2 , pp. 313-318
    • Streubel, B.1    Vinatzer, U.2    Willheim, M.3    Raderer, M.4    Chott, A.5
  • 65
    • 65449136285 scopus 로고    scopus 로고
    • Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas
    • Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol. 2009;33:682-90.
    • (2009) Am J Surg Pathol , vol.33 , pp. 682-690
    • Huang, Y.1    Moreau, A.2    Dupuis, J.3    Streubel, B.4    Petit, B.5    Le Gouill, S.6
  • 66
    • 84876149606 scopus 로고    scopus 로고
    • Inimitable Imatinib: The range of targeted tumours expands to include T-cell lymphoma
    • Turner SD. Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma. Leukemia. 2013;27:759.
    • (2013) Leukemia , vol.27 , pp. 759
    • Turner, S.D.1
  • 67
    • 84857522968 scopus 로고    scopus 로고
    • Final results from a pivotal, multicenter, international open-label, phase 2 study of Romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy
    • Coiffier B, Pro B, Prince M, et al. Final results from a pivotal, multicenter, international open-label, phase 2 study of Romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. J Clin Oncol. 2012;30:631-6.
    • (2012) J Clin Oncol , vol.30 , pp. 631-636
    • Coiffier, B.1    Pro, B.2    Prince, M.3
  • 68
    • 30344470789 scopus 로고    scopus 로고
    • Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures
    • DOI 10.1158/1535-7163.MCT-05-0146
    • Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, et al. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther. 2005;4: 1867-79. (Pubitemid 43056970)
    • (2005) Molecular Cancer Therapeutics , vol.4 , Issue.12 , pp. 1867-1879
    • Mahadevan, D.1    Spier, C.2    Della, C.K.3    Miller, S.4    George, B.5    Riley, C.6    Warner, S.7    Grogan, T.M.8    Miller, T.P.9
  • 69
    • 79751531010 scopus 로고    scopus 로고
    • Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gamma/delta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro
    • Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gamma/delta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 2011;25: 348-58.
    • (2011) Leukemia , vol.25 , pp. 348-358
    • Iqbal, J.1    Weisenburger, D.D.2    Chowdhury, A.3    Tsai, M.Y.4    Srivastava, G.5    Greiner, T.C.6
  • 70
    • 84875373630 scopus 로고    scopus 로고
    • Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endoreduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment
    • Qia W, Spiera C, Liua X, Agarwala A, Cookea LS, Perskyb DO, et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endoreduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res. 2013;37:434-9.
    • (2013) Leuk Res , vol.37 , pp. 434-439
    • Qia, W.1    Spiera, C.2    Liua, X.3    Agarwala, A.4    Cookea, L.S.5    Perskyb, D.O.6
  • 71
    • 84904540138 scopus 로고    scopus 로고
    • Phase II study of Alisertib, a selective Aurora-Kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas
    • Epub ahead of print
    • Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of Alisertib, a selective Aurora-Kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2013 (Epub ahead of print).
    • (2013) J Clin Oncol
    • Friedberg, J.W.1    Mahadevan, D.2    Cebula, E.3    Persky, D.4    Lossos, I.5    Agarwal, A.B.6
  • 72
    • 84899465678 scopus 로고    scopus 로고
    • 55th ASH annual meeting and exposition
    • Ferrando AA, et al. 55th ASH annual meeting and exposition. Blood. 2013;122:811.
    • (2013) Blood , vol.122 , pp. 811
    • Ferrando, A.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.